P. Barton

Cardiomyocyte BRAF and type 1 RAF inhibitors promote cardiomyocyte and cardiac hypertrophy in mice in vivo

Daniel N. Meijles, O. Rackham, A. Clerk, 2021, bioRxiv.

LINC01013 Is a Determinant of Fibroblast Activation and Encodes a Novel Fibroblast-Activating Micropeptide

O. Rackham, N. Whiffin, N. Hubner, 2022, Journal of Cardiovascular Translational Research.

Influence of ethnicity and consanguinity on the genetic architecture of Hypertrophic Cardiomyopathy: insights from an understudied population

J. Ware, N. Whiffin, R. Walsh, 2022, medRxiv.

LINC01013 Is a Determinant of Fibroblast Activation and Encodes a Novel Fibroblast-Activating Micropeptide

O. Rackham, N. Whiffin, N. Hubner, 2022, Journal of Cardiovascular Translational Research.

Evaluation of polygenic score for hypertrophic cardiomyopathy in the general population and across clinical settings

D. O’Regan, Wenjia Bai, A. Marvao, 2023, medRxiv.

The penetrance of rare variants in cardiomyopathy-associated genes: a cross-sectional approach to estimate penetrance for secondary findings

D. MacArthur, L. Bottolo, D. O’Regan, 2023, medRxiv.